A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

StatusRecruiting
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Aug 30, 2026 → Aug 30, 2027
See other at-risk trials from Dana-Farber Cancer Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Aug 30, 2026 to Aug 30, 2027
    • Eligibility criteria expanded, about 21 words
    • Site details revised at 1 of 2 sites
  2. Primary and study completion dates: Aug 30, 2025 to Aug 30, 2026v4
  3. Start date changed from estimate of Nov 2024 to Nov 26, 2024v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2024 to Nov 2024
    • Site details revised at 2 of 2 sites
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery. The study will help understand if the addition of the influenza vaccine could improve the immune system response against the cancer. The names of the study drug involved in this study is: -Fluzone Influenza vaccine (flu shot)
Trial Details
NCT Number NCT06664151
Lead Sponsor Dana-Farber Cancer Institute
Conditions
(from sponsor)		 Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Related terms Skin Neoplasms
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov